FDA Inspection
North American Custom Laboratories, LLC dba FarmaKeio Superior Custom CompoundingNorth American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding – FDA Inspection, Mar 10, 2022
Record Details
This FDA Inspection record concerns North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding, with an inspection on March 10, 2022, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- March 10, 2022
- Product Type
- Drugs
View Company Profile
ID · 06a65fad-a980-4edf-ba27-27c5b321af49
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1164181
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Enforcement
- Warning Letter
FDA Citations
6- Disinfecting materials, aseptic processing area
- Non-sterilized and non-depyrogenated, sterile drug
- Inadequate filter, final product sterilization
- Actionable microbial contamination, adjacent area
- Highly potent drugs, prevention of cross-contamination
- Use of non-pharmaceutical grade components
Full citation text and observation details available on the Dashboard.
Other FDA inspections of North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
1| Date | Classification | Office | Project area |
|---|---|---|---|
| September 5, 2025 | VAI | Dallas District Office | Drug Quality Assurance |
Other documents for North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.